RxDoctor Payments Data

Jamison Jones, DO

Family Medicine · Mesa, AZNPI 1598226698

Payments from drug & device makers

$6,992in general payments, 2019–2025

Across 382 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$848
  • GSK$601
  • Lilly USA, LLC$570
  • Merck$277
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,992 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$115,605
Medicare patients
351
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$98,228
FarxigaDapagliflozin Propanediol34$43,227
JanuviaSitagliptin Phosphate19$27,814
EliquisApixaban16$26,609
MounjaroTirzepatide20$25,793
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$24,378
TrulicityDulaglutide12$13,675
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,239
MyrbetriqMirabegron12$11,827
Tresiba Flextouch U-100Insulin Degludec19$11,379
Breo ElliptaFluticasone/Vilanterol12$4,666
Rosuvastatin Calcium316$3,526
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,323
Atorvastatin Calcium414$3,224
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$3,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$110$98,22868 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,023$55,46753 claims
Lilly USA, LLCMounjaro, Trulicity$570$39,46932 claims
GSKTrelegy Ellipta, Breo Ellipta$601$29,04435 claims
MerckJanuvia$277$27,81419 claims
PfizerEliquis$848$26,60916 claims
Astellas Pharma US IncMyrbetriq$61$11,82712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$2,654267 claims
AbbVieSynthroid$1,064$1,94715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →